METHODS.

RESULTS.
In total, 266 patients were treated with curative intent. The median patient age was 69 years among 219 males and 47 females. The majority of metastatic lymph nodes (162 of 266 lymph nodes; 61%) were located in the parotid with or without cervical lymph node involvement. The median tumor thickness was 6 mm (range, 0.5-28 mm), and the median tumor size was 15 mm (range, 3-70 mm). Most tumors (65%) that measured Ն5 mm in thickness, and 30% of patients had lesions that measured Ն2 cm in greatest dimension. Recurrent cSCC was present in 15% of patients, and most lesions were located within the lymphatic drainage of the parotid on the temple/forehead (28%), on or around the ear (20%), or on the cheek (12%). Forty-six percent of patients had moderately or poorly differentiated cSCC, and 5% of patients were immunosuppressed. A minority of patients (27%) did not have an identifiable index lesion. morbidity of treating patients with metastatic cSCC is considerable, and most require major surgery and adjuvant radiotherapy. 4 The majority of NMSCs (80-90%) arise on the sunexposed HN in older males. Although accurate epidemiologic data are lacking, it is often reported that the incidence of patients with cSCC in the community developing lymph node metastases is low (2-3%). 5, 6 Although this is correct for immunocompetent patients who have small (Ͻ2 cm), thin (Ͻ4 mm), and previously untreated cSCC, this low incidence underestimates the risk to a subset of hospital-referred patients with high-risk cSCC. 7, 8 Patients with high-risk cSCC can be defined as those at a higher risk (Ͼ5%) of developing metastases to lymph nodes of the HN based on unfavorable primary lesion and patient factors. Patients may have 1 or more of the following clinicopathologic factors: thick or deeply invasive lesion (Ͼ4-5 mm), large size (Ͼ2 cm), local recurrence, immunosuppression, highgrade lesion, location on or around the ear, perineural invasion, and lymphovascular invasion.
Patients who develop metastatic cSCC to lymph nodes of the HN are curable, although a sizeable minority will die despite treatment. Identifying and electively treating first-echelon lymph nodes in high-risk patients may prevent the consequences of lymph node metastases. These data from a large data base of patients who were treated at Westmead Hospital (Sydney, New South Wales, Australia) with metastatic cSCC to HN lymph nodes 4, 9 are presented with the objective of identifying high-risk primary lesion and patient factors.
MATERIALS AND METHODS
All eligible patients between 1980 and 2005 who had metastatic cSCC to lymph nodes of the HN (parotid and cervical) and who were treated with curative intent were identified. Since the year 2000, patients have been entered onto a prospective data base. Management decisions were made within the context of the Westmead Hospital multidisciplinary HN Cancer Service. Relevant data regarding the primary lesion were obtained for patients who underwent surgery. Data were analyzed by using SPSS software (version 13; SPSS Inc., Chicago, IL).
RESULTS
Two hundred sixty-six patients were treated for metastatic cSCC to lymph nodes of the HN (Table 1) during the period studied. Most patients were male (219; 82%) with a median age of 69 years (range, 34-95 years). In 72 patients (27%), no obvious index lesion could be identified. Metastatic disease was concurrent with the primary cSCC in 46 patients (17%), with another 148 patients (56%) developing metastases subsequent to treatment of the primary cSCC. In this later group, the median time from primary lesion treatment to the development of lymph node metastases was 11 months (range, 2-37 months). Most patients had metastatic parotid SCC with or without cervical lymph node SCC (162; 61%) or metastatic cervical lymph nodes (Levels ⌱-V; 104 patients; 39%). Treatment of the lymph node metastases in the majority of patients was surgery and adjuvant radiotherapy (212 patients; 80%), and a minority of patients received single-modality treatment (usually surgery).
Primary Lesion Treatment
One hundred ninety-four patients had an identifiable primary cSCC, and most (140 patients; 72%) underwent excision or excision and radiotherapy (41 patients; 21%). A small number of patients received radiotherapy alone (6%).
Primary Lesion Features
Lesion size was documented in 135 patients. The median size was 15 mm (range, 3-70 mm) (Fig. 1) . Using a 2-cm threshold, most patients (70%) had lesions that measured Յ2 cm, and only 30% had lesions that measured Ͼ2 cm. Tumor thickness was documented in 81 patients, and the median thickness was 6 mm (range, 0.5-28 mm) (Fig. 2) . Only 35% of patients recorded a tumor thickness Յ4 mm, and 65% had tumors that measured Ͼ4 mm in thickness. Only a minority of patients (15%) had a recurrent lesion prior to developing metastatic cSCC. Just less than half of the lesions (46%) were moderately or poorly differentiated. The presence of perineural invasion was reported in 8% of patients, and 5% of patients were immunosup- pressed. The ear (20%), frontotemporal scalp (19%), lower lip (15%), and cheek (12%) were the most frequent primary sites (Table 2) .
Correlation
Using the Spearman test, a significant correlation was documented between increasing lesion thickness and tumor size (r ϭ .495) ( Table 3 ).
DISCUSSION
The current clinical tumor, lymph nodes, metastases (TNM) staging system inadequately prognosticates for patients with cSCC, because most patients who de- velop lymph node metastases have T1/T2 primary lesions. Size alone is the only criterion for assigning T classification in patients without invasion of muscle or cartilage (T4). 10 Important features, such as tumor thickness/depth of invasion, histologic grade, or the presence of perineural invasion or lymphovascular invasion, are not considered. Despite this, patients with high-risk cSCC can be identified, and clinicians should be aware so that appropriate management can be considered.
Increasing tumor size is associated with an increasing risk of lymph node metastases. In 1 study, tumor size (Ͻ4 cm vs. Ͼ4 cm; P ϭ .002) predicted for disease-specific survival in 210 patients with cSCC.
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Although some investigators have suggested that size alone is a weak predictor for metastases, 3 many studies have reported a threshold size of Ϸ2 cm (T1 primary lesion), beyond which patients have an increasing propensity to metastasize to lymph nodes. 7, 8, [11] [12] [13] In a series of 97 patients with lower-lip SCC who underwent local excision, 13% developed lymph node metastases. Size (T1 vs. T2-T3) remained a significant predictor of lymph node metastases on multivariate analysis (hazard ratio, 13.5; P ϭ .005). 12 In a series of 200 patients with cSCC who underwent Moh surgery, 12.5% subsequently developed metastatic cSCC, and the authors reported a significant difference in the rate of lymph node metastases from various primary sites of the HN by using a 2-cm threshold size (13% vs. 68%; P ϭ .004). 7 In a large review that reported outcome for patients with cSCC, the metastatic rate was 30% for lesions that measured Ͼ2 cm versus 9% for lesions that measured Ͻ2 cm. 8 In a study of 365 patients with cSCC who also underwent Moh surgery, 7.4% developed metastases, and there was a significant difference in the maximum dimension of lesions between those that metastasized and those that did not (3 cm vs. 2 cm; PϽ.01). 13 In a study of 45 patients with metastatic cSCC to HN lymph nodes, the investigators compared the data with data from nonmetastatic historic controls and observed a difference in the number of patients who had lesions that measured Ͼ2 cm (19% nonmetastatic vs. 81% metastatic). 14 Moore et al. 15 reported that median lesion size was highly significant (3 cm vs. 2 cm; P ϭ .0002) in a study of 40 patients who had metastatic cSCC compared with 153 patients who had cSCC without metastases. The median size of cSCC in our study was 1.5 cm, and only 30% of patients had primary lesions that measured Ͼ2 cm. This suggests that, at least in our current study of Australian patients, even patients with relatively small lesions (Յ2 cm) are at risk of developing metastatic lymph node disease. However, it is noteworthy that 60% of our patients with cSCC lesions measuring Ͻ2 cm also had lesions measuring Ն4 mm in thickness. which may explain the relatively small size compared with other series. We identified a significant correlation between increasing tumor thickness and lesion size, suggesting that cSCC in our study population has a propensity for both vertical and horizontal growth patterns. However, not all large cSCCs will metastasize, and it is possible that cSCC that are large (Ͼ2-3 cm) in horizontal size, but not in thickness, may lack the propensity to metastasize.
Tumor thickness Ͼ4 to 5 mm is an important predictor of lymph node metastases. Similarly, using depth of invasion as a predictor, many investigators have reported a threshold depth of Ͼ4 to 5 mm, beyond which the risk increases significantly. 12, 14, 16, 17 In a study of 95 patients who underwent excision of a lower-lip SCC, there was a significant difference in the mean depth of invasion in lymph node-negative patients compared with patients who developed lymph node metastases (4.2 mm vs. 11.2 mm; PϽ.001). 12 In another study of patients who had metastatic cSCC of the HN, only 17% of patients who had lesions that measured Ͻ4 mm metastasized, compared with 83% of patients who had lesions that measured Ͼ4 mm.
14 Conversely, patients who had tumors that measured Ͻ3 or 4 mm thick had a low incidence of lymph node metastases. 18, 19 In a large study of 550 patients who had 594 cSCCs (including 149 lip SCCs), the investigators reported that 4% of patients developed lymph node metastases, and only 7 patients (2.9%) who had tumors that measured Յ5 mm in thickness developed metastases compared with 14 patients (17.5%) who had tumors that measured Ͼ5 mm in thickness. 20 It is noteworthy that this study had a median follow-up of 5.3 years (minimum, 4 years), and no patients with superficial cSCC (Ͻ2 mm thick) developed metastases. Clark levels also have been analyzed, and 1 group of investigators observed that patients who had metastatic cSCC were significantly more likely (P ϭ .0001) to have lesions beyond Clark level ⌱⌱⌱ compared with patients who did not have metastases. 7 In a large review of prognostic factors in patients with cSCC, those who had tumors that measured Ͻ4 mm or a Clark Level from ⌱ to ⌱⌱⌱ had a metastatic rate of 6.7% compared with 45.7% among patients who had tumors that measured Ͼ4 mm or a Clark level of ⌱V or V. 8 Clayman et al. 11 identified invasion beyond the subcutaneous tissues as an independent predictor of outcome. We documented a median tumor thickness of 6 mm in our patients, with most (65%) having a tumor thickness Ͼ4 mm. Dinehart et al. 21 documented a mean tumor thickness of 6.6 mm in 22 patients with metastatic cSCC with most of those tu-mors associated with contiguous or nearby actinic keratoses.
Recurrent cSCC is associated with a higher incidence of lymph node metastases compared with metastases at initial presentation in 25% to 45% of patients, depending on the site of the recurrence. 7, 8, 16 Patients with an inadequately excised cSCC are at risk of both local recurrence and subsequent lymph node metastases. In a study of patients with lip SCC, those who had recurrent lip SCC experienced a significant difference in lymph node metastases compared with those who did not develop a local recurrence (15% vs. 2%, respectively; PϽ.0001). 22 In a large review of the literature, the incidence of lymph node metastases was 32% and 45% in the setting of recurrent lip SCC and ear SCC, respectively. 8 Clayman et al. 11 reported that recurrent SCCs were larger (2.4 cm vs. 1.5 cm; PϽ.0001) and were significantly more likely to involve perineural invasion (24% vs. 10%), lymphovascular invasion (17% vs. 8%), and invade beyond subcutaneous tissues (30% vs. 10%) compared with nonrecurrent lesions. These findings suggest that recurrent SCC is a biologically more aggressive lesion. In the current study, only 15% of patients developed metastatic disease in the recurrent setting, although we observed no significant differences in important pathologic features between recurrent and nonrecurrent cSCC.
Poorly differentiated cSCC is more likely to be associated with the development of regional metastases. 13, 20, 23 In a study of 571 patients with cSCC, there was a significant difference in the rate of metastases from high-grade cSCC compared with lower grade cSCC (17% vs. 4%, respectively; P ϭ .004). 13 The incidence of poorly differentiated lesions in 1 series of patients with metastatic cSCC was increased significantly in patients who developed metastases (44% vs. 5%, respectively; PϽ.01). 7 Similarly, there also are data demonstrating that desmoplastic SCC, although it is not reported commonly, is an aggressive histologic variant of cSCC with a high propensity to develop regional metastases, especially with increasing tumor thickness. 20, 23 Using the Broder classification, 27% of patients in the study by Breuninger et al. 20 had desmoplastic SCCs that were classified with a grade 4 differentiation compared with only 11% of patients who had nondesmoplastic cSCC. In the current study, almost half of the patients (46%) had tumors that were classified as moderately/poorly differentiated, and only 12% had tumors that were classified as well differentiated.
Perineural invasion occurs in approximately 5% to 10% of patients with cSCC and is usually an incidental finding, although a small subset of patients may present with intracranial spread and malignant cranial neuropathies. 24 There is also a greater incidence of lymph node metastases compared with patients who do not have perineural invasion. 7, 19 In 1 study, there was a significant increase in both regional metastases (35% vs. 15%; PϽ.0005) and distant metastases (15% vs. 3.3%; PϽ.0005) for patients who were diagnosed with perineural invasion compared with patients who were not diagnosed with perineural invasion. 25 Similarly, the presence of perineural invasion independently predicted for a worse 3-year disease-specific survival rate (64% vs. 91%; P ϭ .002) in another study of 210 patients. 11 In total, 277 lesions were treated, and, perineural invasion was identified in 14% of patients. In a study of 135 patients who received radiotherapy with or without surgery, half of all failures in patients with microscopic perineural invasion were in regional lymph nodes, prompting the investigators to recommend elective lymph node treatment. 26 In a study that compared the prognostic features of patients with metastatic and nonmetastatic lip SCC, a highly significant difference in the presence of perineural invasion also was observed (41% vs. 5%, respectively; PϽ.0001). 19 Similarly, in another study of patients with HN cSCC, the rate of perineural invasion differed between patients with and without lymph node metastases (40% vs. 18%, respectively; P ϭ .005). 15 In the current study, missing data precluded any strong conclusions on the presence of perineural invasion and the development of metastatic lymph nodes.
Recent evidence suggests that patients with cSCC who exhibit lymphovascular invasion are at higher risk of developing lymph node metastases. Moore et al. documented lymphovascular invasion as an independent predictor of lymph node metastases on multivariate analysis (odds ratio, 7.54; PϽ.00001). 15 In their study, 40% of patients with lymph node metastases had lymphovascular invasion compared with 8% of lymph node-negative patients. Other studies of highrisk cSCC also reported the presence of lymphovascular invasion, although they failed to find any significant impact on outcome. 3, 7, 11 Lesions on or around the ear are considered to have a higher incidence of lymph node metastases. 8, 27, 28 There are advocates of elective lymph node dissection in select high-risk patients who have lesions located in the ear/preauricualr region. 28 -31 In a study of 38 patients with external ear cSCC who were treated predominantly with surgery, the authors reported a 53% recurrence rate, with almost half metastasizing to regional lymph nodes, and recommended prophylactic parotidectomy and neck dissection with or without radiotherapy in patients with poor prognostic fea-tures, such as cartilage invasion, deep invasion, or poor differentiation. 30 Most metastatic lymph nodes from HN cSCC occur in the parotid gland, which is considered the metastatic basin for cSCC of the HN, with high-risk sites draining through lymphatic vessels located on or around the ear, cheek, or temple/forehead. 32 We observed that most index lesions (56%) arose in this at-risk area. In concordance with our findings, researchers from The University of Texas M. D. Anderson Cancer Center also reported that, among 40 patients who had lymph node-positive cSCC, most lesions metastasized to the parotid with or without the neck (70%), and the majority of primary lesions (52%) were located in the parotid drainage (periauricular or frontotemporal scalp). 15 Nearly 30% of our patients did not have an identifiable index lesion. In all patients, clinical examination involved inspection of the upper aerodigestive tract, especially in patients with cervical metastases, to exclude a mucosal primary lesion. Many patients had widespread actinic changes, and it is possible that metastatic disease developed as a result of a small superficial or occult cSCC. There were no marked demographic differences in this group of patients compared with patients who had an index lesion. The median tumor size was 12 mm among patients with cSCCs that measured Ͻ4 mm in thickness in the current study, suggesting that even patients with small and superficial lesions have metastatic potential. Differences at a molecular level may explain in part the metastatic potential of cSCCs that lack the established high-risk features, such as size and thickness. This also may explain why relatively small, thin cSCCs still can metastasize, and the overexpression of epidermal growth factor receptor has been postulated as a possible factor. 33 Further research will be required into this area, so that a clearer understanding of the biology of metastatic cSCC can be elucidated.
Immunosuppression, particularly in the setting of organ transplantation, often leads to significant morbidity from NMSCs. An Australasian group reported a 66% probability of developing a cutaneous malignancy by 24 years postrenal transplantation. 34 A subset of cSCCs in immunosuppressed patients is aggressive in nature with rapid growth and the development of regional and distant metastases. In an Australian study of 619 cardiothoracic transplantation recipients, 26 patients developed an aggressive NMSCs, and most were diagnosed as poorly differentiated cSCC. 35 Death occurred in 13 of 26 patients, including 10 patients who died from systemic disease. Martinez et al. 36 reported the outcome of 60 organ transplantation recipients with metastatic skin cancer (85% cSCC). In keeping with our data, albeit in a mainly immunocompetent population, 27% of their patients also had an unknown primary lesion. In that study, the median primary lesion size was 12 mm, and the median depth was 3.2 mm. The 3-year disease-specific survival was only 56%. Those results suggest a lower lesion size and depth of invasion threshold for the development of metastatic cutaneous cancer compared with immunocompetent patients. Only a minority of our patients (5%) in the current study was immunosuppressed, but we also found a smaller lesion size (median, 13 mm) and thickness (median, 5 mm) compared with immunocompetent patients. The rate of recurrent cSCC also was higher (39% vs. 15%).
Observation and expectant treatment often are presented as options in patients with high-risk cSCC. However, there are analogous data from patients with high-risk mucosal HN SCC suggesting that even, with close follow-up, patients who experience lymph node recurrence often present with advanced (often incurable) lymph node disease. 37 Even with combined treatment in patients with operable, metastatic cSCC, the 5-year disease-free survival rate is approximately 70% to 75%. 4 The concept of sentinel node biopsy (SNB) has evolved in other malignancies, such as melanoma and breast cancer, to identify patients with spread to firstechelon lymph nodes. There are emerging data that SNB also has a role in identifying patients with highrisk cSCC. 38, 39 In series of 9 patients with high-risk cSCC, 4 of 9 patients (44%) had positive SNB findings, and 2 patients subsequently died of metastatic disease. All lymph node-positive patients had cSCC that measured Ͼ3 cm in greatest dimension and Ͼ8 mm in depth. The 5 patients who had negative SNB findings remained disease free, although their median followup of 8 months was short. 38 In another series of 24 patients with high-risk NMSC (n ϭ 17 cSCCs) who underwent SNB, 7 patients (29%) had a positive sentinel node, and there was only 1 false-positive result. 39 This included 5 SCCs with positive SNB findings, although only 2 lesions involved HN lymph nodes. The role of SNB in patients with high-risk cSCC is evolving and may be an option in select patients who are treated by experienced operators, but it still requires further validation.
Electively irradiating lymph nodes also is an option, although high-level supportive evidence is lacking. Kwan et al. 40 reported a higher locoregional failure rate (30% vs. 20%) among 37 patients with advanced cSCC who did not receive lymph node irradiation compared with 5 patients who received elective lymph node treatment. Other proponents also have recommend elective lymph node treatment in the presence of adverse or high-risk features. 15, 20, 26, 30, 32 A weakness of this current study is a lack of a control group of patients with cSCC who did not have metastatic lymph node disease, and another weakness is the retrospective nature of much of the data. Despite these issues, we believe that the data from this large study of patients with metastatic cSCC lymph nodes of the HN, in concordance with the results of others, strongly suggest that there is a set of unfavorable pathologic and patient factors that places a patient with cSCC at high risk of developing metastatic lymph node cSCC.
In conclusion, the TNM staging system fails to prognosticate for patients with cSCC. Size alone is a poor predictor of outcome, because the majority of patients in the current study had T1 cSCC. Lesions located in the parotid drainage area or basin with a thickness Ͼ4 mm to 5 mm are at risk of metastasizing to lymph nodes. Recurrent lesions increase this risk.
Other factors, such as histologic grade, perineural and lymphovascular invasion, and immunosuppression, also need to be considered. However, predicting which patients are at high risk and justifying the elective treatment of first-echelon lymph nodes are difficult. Despite these difficulties, elective treatment may be life saving, and referral to a multidisciplinary head and neck cancer service with experience in treating skin cancer is encouraged.
